Enhanced CT, DTI, and 1H-MRS Assisted Robot-Guided Brain Glioma Biopsy: A Single-Center Study

Abstract

Abstract Objective To explore the positive rate of pathological results and safety of enhanced CT, DTI, and 1H-MRS assisted robot-guided brain glioma biopsy. Methods Eighteen patients with imaging-diagnosed brain gliomas who underwent robot-guided brain glioma biopsy in the Department of Neurosurgery of Baise People's Hospital from January 2021 to October 2022 were selected as the study subjects. All patients underwent preoperative examinations such as enhanced CT, DTI, and 1H-MRS. The neurosurgical robot Reme-Studio automatically fused the image pictures, using the principles of enhanced CT vascular imaging points, DTI reconstructed conduction bundle three-dimensional stereograms, and 1H-MRS indicating the tumor cells, to perform robot-guided brain glioma biopsy. The specimens were sent to the pathology department for routine pathological results, and the positive rate of specimens and postoperative complications were recorded. Results All 18 patients obtained clear pathological grades, and no intracranial bleeding requiring emergency surgery or new-onset neurological dysfunction occurred after surgery. Conclusion Enhanced CT, DTI, and 1H-MRS assisted robot-guided brain glioma biopsy can accurately locate and puncture the metabolic hotspots of the edema zone, marginal zone, and tumor body CHo/NAA maximum value, avoiding important blood vessels and conduction bundles. It is not only an important method to improve the positive rate of pathological results but also safe and reliable.